Exelixis Inc. – Material Contracts Watch

from 10-K 6 pages Fourth Amendment to Collaboration and License Agreement

from 10-K >50 pages Amended and Restated Collaboration and License Agreement This Amended and Restated Collaboration and License Agreement (The “Agreement”) Is Entered Into as of December 17, 2025 (The “Restatement Date”), by and Between Exelixis, Inc., a Delaware Company Having an Address at 1851 Harbor Bay Parkway, Alameda, Ca 94502, USA (“Exelixis”) and Ipsen Pharma Sas, a French Corporation Having an Address at 70 Rue Balard, 75015 Paris, France (“Licensee”). Exelixis and Licensee May Be Referred to Herein Individually as a “Party” or Collectively as the “Parties”. Recitals Whereas, Exelixis, a Biopharmaceutical Company, Is Developing Its Proprietary Compound Known as Cabozantinib for the Treatment of Cancer, and Owns or Controls Certain Patents, Know-How and Other Intellectual Property Relating to Such Compound; Whereas, Licensee, a Fully-Integrated Pharmaceutical Company, Possesses Substantial Resources and Expertise in the Development and Commercialization of Pharmaceutical Products; and Whereas, Exelixis and Licensee Are Parties to That Certain Collaboration and License Agreement Dated February 29, 2016 (The “Effective Date”), as Subsequently Amended by the First Amendment Dated Effective December 20, 2016, Second Amendment Dated Effective September 14, 2017, Third Amendment Dated Effective October 26, 2017, Fourth Amendment Dated Effective October 11, 2022 (The “Fourth Amendment Effective Date”), and Fifth Amendment Dated Effective August 24, 2023 (The “Fifth Amendment Effective Date”) (Collectively, the “Original Agreement”) Under Which the Parties Have Been Collaborating on the Development and Commercialization of Cabozantinib; Whereas, the Parties Wish to Amend and Restate the Original Agreement in Accordance With Section 17.2 Thereof to Incorporate the Amendments, All Under the Terms and Conditions

from 10-K 15 pages Separation Agreement

from 10-K 2 pages Material contract

from 10-Q >50 pages Performance-Based Restricted Stock Unit Grant Notice Exelixis, Inc. 1851 Harbor Bay Parkway Alameda, Ca 94502 Participant: Award #: Award Type: Plan: Shares Granted: Performance-Based Restricted Stock Units 2017 Equity Incentive Plan

from 10-Q 14 pages Exelixis, Inc. 2000 Employee Stock Purchase Plan

from 10-K 26 pages Exelixis, Inc. Change in Control and Severance Benefit Plan

from 10-K 1 page Cash Compensation Information for Non-Employee Directors Exelixis, Inc. Cash Compensation for Non-Employee Directors

from 10-K 3 pages Material contract

from 10-Q 1 page Exelixis, Inc. Cash Compensation Information for Non-Employee Directors

from 10-Q 17 pages Confidential Separation Agreement and Release of All Claims

from 10-Q 7 pages Fifth Amendment to Collaboration and License Agreement

from 10-Q 30 pages Exelixis, Inc. Change in Control and Severance Benefit Plan

from 10-K 4 pages Fourth Amendment to Collaboration and License Agreement

from 10-K 1 page Terms of Employment – Dana T. Aftab

from 10-Q ~5 pages Cash Compensation Information for Non-Employee Directors Exelixis, Inc. Cash Compensation for Non-Employee Directors

from 10-Q 18 pages Seventh Amendment to Lease Agreement

from 10-Q ~5 pages Cash Compensation Information for Non-Employee Directors Exelixis, Inc. Cash Compensation for Non-Employee Directors

from 10-Q 28 pages Exelixis, Inc. 2017 Equity Incentive Plan Adopted by the Board of Directors: February 23, 2017 Amended by the Compensation Committee: March 22, 2017 Approved by the Stockholders: May 24, 2017 Amended by the Company: December 18, 2017 Amended by the Compensation Committee: March 18, 2020 Approved by the Stockholders: May 20, 2020 Amended by the Board of Directors: April 1, 2022 Approved by the Stockholders: May 25, 2022

from 10-Q 4 pages Second Amendment to Collaboration and License Agreement